Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants
Status:
Not yet recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the potential drug interactions between ALXN2050 and cyclosporine
(Part 1), between ALXN2050 and tacrolimus (Part 2), and between ALXN2050 and mycophenolate
mofetil (MMF) (Part 3).